MTHFD1L

Across TCGA pan-cancer cohorts, MTHFD1L Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MTHFD1L data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MTHFD1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTHFD1L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and HNSC are the cancer types where MTHFD1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.076	0.844	<.001	48	view →
UCEC	DFS	Median	All	0.971	0.608	.003	30	view →
HNSC	DFS	Median	All	0.201	0.605	.009	24	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
BLCA	OS	Median	III,IV	0.174	0.584	<.001	15	view →
PRAD	DFS	Median	All	0.617	0.886	.027	6	view →
COAD	DFS	Median	All	0.393	0.701	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MTHFD1L–OV (OS)

Open the OV breakdown →